You Can't Learn to Scale in a Country Where Nobody Scales

In August, the Council of Canadian Innovators | Conseil canadien des innovateurs (CCI) published The Scale-Up Gap, based on interviews with 31 founders of 30 Canadian companies that were sold to foreign buyers. The companies weren't failing. They had proven demand and real revenue. But in 28 of those 30 companies, leadership and strategic control left Canada after the sale. That's more than 28 lost headquarters. It's 28 executive teams whose next and hardest lessons, how to run a company at real scale, will be learned somewhere else.

Founders named four barriers that pushed them toward a foreign sale: finding domestic customers, raising growth capital, a disjointed scale-up system, and access to specialized talent. I've written about customers and capital. Talent gets less attention because a cheque can't fix it. It quietly feeds the other three.

𝗧𝗵𝗲 𝗹𝗼𝗼𝗽

Scaling is learned by doing. Very few executives learn in a classroom how to take a company through a crossover round, build a commercial team across three markets, or run a global launch. They learn it inside a company that is scaling.

Canada has few companies at that stage, so few Canadians get that experience. Without those people, the next promising company struggles to scale. When a foreign offer arrives, selling looks safer than building. The company sells, leadership moves abroad, and the pool of scale-stage experience shrinks again. It's inertia with a feedback loop.

The report makes an important distinction. Founders didn't describe Canada as short of capable people. They described trouble getting specialized talent quickly enough to keep pace with growth, plus the immigration and relocation friction of recruiting from abroad. The capability exists in pieces. What's missing is a way to put the right experience into the right company at the right moment.

𝗪𝗵𝗮𝘁 𝗲𝘅𝗶𝘀𝘁𝘀 𝘁𝗼𝗱𝗮𝘆

Canada isn't starting from zero. adMare BioInnovations Executive Institute has run since 2018 with cohorts of about 20 life sciences leaders, and its alumni network now spans nearly 150 leaders across more than 100 organizations. It builds skills and networks, and the sector is better for it.

Ireland shows how far a country can take the idea. Enterprise Ireland's Leadership 4 Growth programme has run since 2006. It sends CEOs of high-potential companies through state-subsidized executive education abroad, and each participant gets a coach who works with them on applying the frameworks in their own company. Enterprise Ireland also runs a separate programme built specifically for CFOs and finance leaders who need to scale in global markets.

In the US, St. Louis diagnosed a problem that will sound familiar. The region had research and funding but lacked experienced life sciences startup leaders, so BioGenerator built a venture fellowship to develop operators locally.

Canada's policy attention points the other way. Budget 2025 committed up to $1.7 billion to recruit roughly 1,000 international researchers and academics. That's talent for the discovery end of the pipeline. Meanwhile, the one Canadian tax measure aimed squarely at commercial expertise has been wound down. Quebec's tax holiday for foreign experts covered specialists in commercialization, technology transfer and R&D financing, and it stopped accepting new applications in March 2025.

The federal Pharmaceutical and Life Sciences Sector Task Force's 39 recommendations include a late-stage scale-up capital vehicle and a definition of "anchor companies" tied to Canadian headquarters and leadership presence. None of them sets out how Canada will develop the leaders those companies need.

𝗧𝗵𝗲 𝗺𝗶𝘀𝘀𝗶𝗻𝗴 𝗽𝗶𝗲𝗰𝗲

Each of these programs teaches the skills. None of them solves the underlying problem: you can't practise scaling without a company that's scaling. A curriculum and a network are valuable, but they don't replace the experience of actually doing it.

The missing piece is placement. Scale-stage experience needs to go into Canadian companies at the moment they need it, and it needs to stay after the program ends.

𝗧𝗵𝗲 𝗦𝗰𝗮𝗹𝗲-𝗦𝘁𝗮𝗴𝗲 𝗘𝘅𝗲𝗰𝘂𝘁𝗶𝘃𝗲 𝗙𝗲𝗹𝗹𝗼𝘄𝘀𝗵𝗶𝗽

Here's what a fellowship built around placement would look like:

✅ Bring proven operators in. Recruit executives who have already scaled companies, including Canadians working abroad, into 18- to 24-month placements as CFO, commercial lead, or COO at Canadian scale-ups. Cost-share their salary during the fellowship so a Series B company can afford a leader it couldn't otherwise attract.

✅ Pair every fellow with an understudy. Each placement includes a named Canadian successor who works alongside the fellow and takes over the role. The measure of success is whether the successor is ready, not whether the fellow stays.

✅ Send Canadian executives out and bring them back. Offer outbound secondments of six to twelve months inside global companies that have already scaled, with a firm commitment to return. Canada gets the experience without losing the person.

✅ Let investors choose the companies. Tie eligibility to arm's-length equity, so government matches the diligence of private investors instead of trying to pick winners. Life Sciences Ontario's Ideas to Action 2025 report makes the same recommendation for public support generally.

✅ Build retention into the terms. Tie fellowship incentives and equity vesting to keeping the company headquartered in Canada, and fast-track immigration for incoming fellows so recruiting talent doesn't take longer than the growth window allows.

Why not leave this to the market? Because the market is what built the loop. Left alone, it will keep training Canada's next generation of scale-stage leaders inside someone else's company.

𝗧𝗵𝗲 𝗽𝗼𝗹𝗶𝗰𝘆 𝗹𝗲𝘃𝗲𝗿𝘀

A fellowship on its own is a program. These changes would make scale-stage leadership worth building here:

✅ A federal scale-stage expert tax holiday. Quebec already wrote the template: a deduction of 100% of salary in the first two years, stepping down to 75%, 50% and 25%. Apply the same structure federally to fellows, both foreign executives and Canadians returning after years abroad. Tight eligibility keeps the cost contained.

✅ A refundable Scale-Stage Leadership Credit for the company. Cover a share of the fellow's salary for the length of the placement. Make it refundable so pre-revenue companies benefit, and make it conditional on a named successor.

✅ A scale-stage stream inside the talent attraction strategy. IRCC is providing priority work-permit processing and dedicated account managers for the researcher recruitment initiative. Scale-stage executives and their families should get the same treatment.

✅ Equity that keeps working after a foreign raise. Equity is how scale-ups pay senior people. Companies can lose Canadian-controlled private corporation (CCPC) status once foreign investors take control, and with it enhanced SR&ED refundability and favourable stock option treatment. Preserving those benefits for companies that meet the Task Force's anchor criteria would remove a penalty for raising the capital they need.

✅ A retention clawback. If a company moves its headquarters or leadership abroad within five years of a placement, the public share of the fellowship is repaid. That makes the fellowship a bet on building in Canada, not a subsidy to the eventual acquirer.

✅ Put talent in the Task Force's implementation mandate. The Task Force proposes an Anchor Company Scaling implementation team. That team should own leadership talent alongside capital, because the two fail together.

𝗠𝗮𝗸𝗶𝗻𝗴 𝗶𝘁 𝘄𝗼𝗿𝗸

The details decide whether this becomes a working pipeline or one more program on a long list:

✅ An independent operator, not a department. Government funds it, an independent organization runs the matching, and investors nominate companies. Nobody in Ottawa picks winners.

✅ Real roles, not advisory titles. Fellows are employees in named executive roles reporting to the board. Advisory or part-time arrangements don't qualify. The point is to do the job, not comment on it.

✅ A succession plan on day one. Each placement starts with a written, board-approved plan for the understudy, reviewed every six months.

✅ A teaching layer built on what exists. Fellows and understudies meet as a cohort throughout the placement. Programs like adMare's Executive Institute could deliver that layer, which pairs classroom learning with real-world practice instead of competing with it.

✅ Global companies as hosts. The Task Force's membership includes the heads of most major pharmaceutical companies' Canadian operations. Hosting outbound secondments for Canadian executives, who then return home, is a concrete contribution those companies could make.

✅ Start narrow and publish the results. As a starting proposal, run a three-year pilot in life sciences and health technology with around 15 placements. Evaluate it independently and report publicly against the three measures below.

𝗛𝗼𝘄 𝘄𝗲'𝗱 𝗸𝗻𝗼𝘄 𝗶𝘁'𝘀 𝘄𝗼𝗿𝗸𝗶𝗻𝗴

Graduation numbers won't show it. Three measures will: how many successors are still in their roles three years after a placement, how many fellowship companies remain headquartered in Canada five years later, and how many fellowship alumni take a second scale-stage role at another Canadian company. That last number shows whether the loop has started running the other way.

Every Canadian company that scales here trains the executives who help the next one scale. Every company we sell early trains them for someone else.

📰 LinkedIn Newsletter: https://bit.ly/BIPLinkedInNewsletter

🎧 Podcast: https://augmentios.com/podcast

#BreakingInnovationParalysis #LifeSciences #ScaleUp #InnovationPolicy #CanadianInnovation

𝗦𝗼𝘂𝗿𝗰𝗲𝘀

Council of Canadian Innovators, The Scale-Up Gap: From Value Creation to Value Retention (August 2026), with Impact Group, DataAngel Policy Research, Yvan Clermont and LABmedia Consulting. Coverage: https://betakit.com/canadian-tech-firms-are-selling-to-foreign-buyers-when-its-time-to-scale-cci-says/

adMare BioInnovations, Executive Institute: https://www.admarebio.com/en/executive-institute

Enterprise Ireland, Capability Development programmes, including Leadership 4 Growth: https://www.enterprise-ireland.com/en/supports/capability-development

BioGenerator Ventures, Venture Fellows Program: https://www.biogeneratorventures.com/news-media/biotech-journey-through-venture-fellows-program-with-grant

Life Sciences Ontario, Ideas to Action 2025 report: https://www.lifesciencesontario.ca

Immigration, Refugees and Citizenship Canada, Talent Attraction briefing to the Standing Committee on Citizenship and Immigration (December 4, 2025): https://www.canada.ca/en/immigration-refugees-citizenship/corporate/transparency/committees/cimm-dec-04-2025/talent-attraction.html

Revenu Québec, Foreign Employees Entitled to a Five-Year Tax Exemption: https://www.revenuquebec.ca/en/businesses/source-deductions-and-employer-contributions/special-cases-source-deductions-and-employer-contributions/foreign-employees-entitled-to-a-five-year-tax-exemption/

Raymond Chabot Grant Thornton, Tax Planning Guide: Foreign Specialists, Quebec: https://www.rcgt.com/en/tax-planning-guide/sections/section-05-employees/foreign-specialists-quebec/

Government of Canada, Pharmaceutical and Life Sciences Sector Task Force: Report to the Ministers of Health and Industry (2026): https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/pharmaceutical-life-sciences-sector-task-force/report-ministers-health-industry.html